CeaPro
Presença
CeaPro é uma empresa listada sob o símbolo CZO (CA).
Executivos
Veja o organograma con seus 11 executivos principais
Biografias mais buscadas da CeaPro
- Gilles Gagnon, President, Chief Executive Officer and Director
- Ulrich Kosciessa, Director
- Geneviève Foster, Director
Criar um alerta
para seguir os movimentos de executivos da CeaPro.
Biotecnologia
CeaPro possui 2.284 concorrentes concorrentes Lonza (Suíça), Eurofins (Luxemburgo) e Adaptive Phage Therapeutics (Estados Unidos).
Popular M&A news in Biotecnologia
- Karius acaba de anunciar uma arrecadação de fundos de 100 milhões de dólares. (publicado em 3 de maio de 2024).
- Transcarent acaba de anunciar uma arrecadação de fundos de 126 milhões de dólares. (publicado em 2 de maio de 2024).
- WindRose Health Investors has announced the acquisition of SubjectWell (publicado em 2 de maio de 2024).
Outros contatos sugeridos na indústria do Biotecnologia
Notícias
Últimos comunicados de imprensa de CeaPro
- Ceapro Receives Final Court Approval for Merger with Aeterna Zentaris :: Ceapro Inc.
- Aeterna Zentaris and Ceapro Merger Approved by Securityholders at Special Meetings :: Ceapro Inc.
- Ceapro Provides Business Update on Progress of Ongoing Development Programs, Technology and Cosmeceutical Base Business :: Ceapro Inc.
- Leading Independent Proxy Advisory Firm ISS Recommends Aeterna Zentaris and Ceapro Securityholders Vote FOR the Arrangement Agreement to Approve the Merger of Equals to Create a Diversified Biopharmaceutical Company :: Ceapro Inc.
- Ceapro Inc. Announces the Mailing of Meeting Materials in Connection With the Special Meeting of Securityholders to Approve Merger With Aeterna Zentaris :: Ceapro Inc.
- Aeterna Zentaris and Ceapro Announce Merger of Equals to Create a Diversified Biopharmaceutical Company :: Ceapro Inc.
- Ceapro Inc. Announces Dosing of First Patients in Phase 1-2a Study Assessing Flagship Product Avenanthramides for Potential Applications in Inflammation Based Diseases :: Ceapro Inc.
- Ceapro Inc. Initiates Phase 1-2a Study Assessing Its Flagship Product Avenanthramides for Potential Applications in Inflammation Based Diseases :: Ceapro Inc.
- Ceapro Inc. Reports 2023 Third Quarter and Nine-Month Financial Results and Operational Highlights :: Ceapro Inc.
- Ceapro Inc. Enters into Technical Collaboration with NATEX Prozesstechnologie GmbH and Provides Update on the Scale-Up Project for its Patented Pressurized Gas eXpanded (PGX) Technology :: Ceapro Inc.
- View more press releases Close
Redes sociais sobre CeaPro
- CeaPro na Wikipedia, Google News e Yahoo Finance
- CeaPro na LinkedIn, Twitter e YouTube
Entrar em contato
Contate seus executivos por e-mail agora, incluindo Gilles Gagnon 
Ligue para a CeaPro em +1 780...
